Name: NeuroSense Therapeutics Ltd. (NRSN) Financial Statements
Creator: FinSpry

NeuroSense Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

NeuroSense Therapeutics Ltd. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	0.00	0.00	-0.08	0.00	0.00
Gross Profit	0.00	0.00	0.08	0.00	0.00
Operating Expenses
Research & Development	5.70	7.27	5.59	3.08	2.50
Selling, General & Administrative	4.20	4.78	7.14	2.51	0.39
Operating Expenses	9.90	12.05	13.55	5.59	2.89
Operating Income	-9.90	-12.05	-13.55	-5.59	-2.89
Other Income/Expense
Interest Income	0.00	0.18	0.09	0.00	0.00
Interest Expense	0.31	0.01	0.02	0.00	0.00
Other Income/Expense	-0.31	2.21	0.05	2.70	0.00
Income
Income Before Tax	-10.21	-10.11	-12.34	-4.04	-2.83
Income Tax Expense	0.00	0.00	0.00	0.00	0.00
Net Income	-10.21	-10.11	-12.34	-4.04	-2.83
Net Income - Continuous Operations	-10.21	-10.11	-10.49	-4.04	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-9.88	-12.03	-12.25	-4.04	-2.89
EBIT	-9.90	-12.05	-12.34	-4.04	-2.89
Depreciation & Amortization	0.02	0.02	-0.15	0.00	0.00
Earnings Per Share
Basic EPS	-1.00	-1.00	-1.00	-1.00	-1.00
Diluted EPS	-1.00	-1.00	-1.00	-1.00	-1.00
Basic Shares Outstanding	18.60	13.64	11.53	6.24	5.52
Diluted Shares Outstanding	18.60	13.64	11.53	6.24	5.52